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Noncoding expansions of a hexanucleotide repeat
(GGGGCC) in theC9orf72 gene are themost common
cause of familial amyotrophic lateral sclerosis and
frontotemporal dementia. Here we report transgenic
mice carrying a bacterial artificial chromosome
(BAC) containing the full human C9orf72 gene with
either a normal allele (15 repeats) or disease-associ-
ated expansion (100–1,000 repeats; C9-BACexp).
C9-BACexp mice displayed pathologic features seen
in C9orf72 expansion patients, including widespread
RNA foci and repeat-associated non-ATG (RAN)
translated dipeptides, which were suppressed by
antisense oligonucleotides targeting human C9orf72.
Nucleolin distribution was altered, supporting that
eitherC9orf72 transcripts or RANdipeptides promote
nucleolar dysfunction. Despite early and widespread
production of RNA foci and RAN dipeptides in
C9-BACexp mice, behavioral abnormalities and neu-
rodegeneration were not observed even at advanced
ages, supporting the hypothesis that RNA foci and
RAN dipeptides occur presymptomatically and are
not sufficient to drive neurodegeneration in mice at
levels seen in patients.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar
degeneration (FTLD) are disorders with overlapping clinical
presentation, genetics, and pathology (Chen-Plotkin et al.,
2010). ALS is a form of motor neuron disease that leads to
muscle wasting with spasticity from loss of upper and lower
motor neurons, while FTLD patients typically develop behav-
ioral and language disturbances due to frontal and temporal892 Neuron 88, 892–901, December 2, 2015 ª2015 Elsevier Inc.cortical degeneration. Expansions of a GGGGCC hexanucleo-
tide repeat in the first intron/promoter of the C9orf72 gene
are the most commonly identified genetic cause of both famil-
ial and sporadic ALS and FTLD (DeJesus-Hernandez et al.,
2011; Renton et al., 2011). More recently, C9orf72 repeat
expansions were reported in other diseases, including Alz-
heimer’s disease, Parkinson’s disease, corticobasal syndrome,
Lewy body dementia, and Huntington-like syndromes (Cooper-
Knock et al., 2014).
It remains uncertain whether the repeat expansion in C9orf72
causes neurodegeneration primarily through a toxic gain of func-
tion, loss of function, or both. The repeat is transcribed in both
the sense and antisense directions and leads to accumulations
of repeat-containing RNA foci in patient tissues (Gendron
et al., 2013). These RNA foci may bind RNA binding proteins
and alter RNA metabolism (Donnelly et al., 2013; Lee et al.,
2013; Sareen et al., 2013), and aborted transcripts containing
the repeat can also disrupt nucleolar function (Haeusler et al.,
2014). Additionally, simple dipeptide repeats (DPRs) can be
generated by repeat-associated non-ATG-dependent (‘‘RAN’’)
translation of both the sense and antisense strands that have a
variety of toxic effects (Ash et al., 2013; Mori et al., 2013). While
it is clear that high levels of exogenous of DPR proteins (GA or
GR/PR) can be toxic to cells, it remains unclear whether they
can do so at the lower levels at which they are present in human
tissues and CSF (Su et al., 2014).
Here we generated transgenic mice that express the
C9orf72 hexanucleotide repeat in the context of the normal
genetic control elements driven from a bacterial artificial chro-
mosome (BAC) isolated from a C9orf72 expansion patient.
We observed sense and antisense transcription of the repeat
with development of RNA foci, as well as production of DPR
protein levels similar to those seen in C9orf72 FTLD patient
tissues, but without the development of neurodegeneration.
These data suggest that RNA foci and RAN translation
occur presymptomatically in patients and are not sufficient to
drive neurodegeneration in the absence of other stressors or
overexpression.
A~110 kb ~2
0 
kb
Human C9orf72
8.128 kb
173.681 kb
pCC1BACTM
B
F1
01
F1
19
F1
12
F1
22
F1
26
F1
29
F1
15
F1
28
F1
24
F3
05
F1
14
F1
18
B
ra
in
B
ra
in
S
pl
ee
n
C
TR
 B
A
C
F1
13
F08-CTR
kb
10
12
8
6
4
2
(GGGGCC)n
E F
0
20
40
60
%
 M
et
hy
la
tio
n
R
el
at
iv
e 
hC
9o
rf7
2 
m
R
N
A 
ex
pr
es
si
on
0
5
10
15
NTg F112 F113
F08-
CTR
C D
0.0
0.5
1.0
1.5
2.0
2.5
N
or
m
al
iz
ed
 e
xp
re
ss
io
n
C9orf72
Actin
Human C9orf72 (28i) 
Exon 1a Exon 1b
CBAC mice
Exon 1a Exon 1b
Exon 1a Exon 1b
Exon 1a Exon 1b
F08-CTR
F113
F112
Figure 1. Generation of C9orf72 BAC Transgenic Mice
(A) Schematic diagram of C9-BAC construct. The pCC1BACbackbone (8.128 kb) was used to isolate a region containing the entire humanC9orf72 gene (36 kb)
from a patient with C9-ALS, including 110 kb upstream and 20 kb downstream. More than 30 different C9-BAC founder lines were generated with either the
contracted control BAC (15 repeats) or expansions of various sizes.
(B) Southern blot analysis of the repeat length in C9-BAC founder lines. A contracted subclone was used to generate the control (F08-CTR) line with 15 GGGGCC
repeats. Lines F08-CTR, F112, and F113 showed comparable expression, and lines F112 and F113 had a variety of repeat sizes ranging from 100–1,000.
(C) Relative expression of human C9orf72 mRNA in cortex from C9-BAC transgenic lines measured by qPCR.
(D)Western blot analysis of C9orf72 protein (48 kDa) expressed in C9-BACmouse cortex (left). Anti-C9orf72 (top) and anti-actin (bottom) and shown.Western blot
quantitation (right) normalized to nontransgenic (NTg) control.
(E) Sequence alignments of exon 1a and exon 1b utilization from 50RACE analysis ofC9orf72 transcripts. iPSC-derived motor neurons are shown on the left (from
BAC donor patient) to demonstrate exon 1a and 1b utilization in human cells.
(F)C9orf72 promoter methylation assay as assessed byMSRE-qPCR. Fibroblasts (Fibro), induced pluripotent stem cells (iPSC), and iPSC-derivedmotor neurons
(MN) are shown for BAC donor patient (800 repeats), which revealed variable methylation from 10% in fibroblasts to 50% in iPSC and MNs. Methylation
levels were low (5%) in C9-BAC transgenic lines. Lymphoblastoid cell lines (LCL) from a non-expanded patient (CTR) and C9orf72 expansion carrier (C9+) are
shown for comparison.
All data are shown as mean ± SEM. See also Figure S1.
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Figure 2. C9-BAC Transgenic Mice Develop RNA Foci and RAN Peptides Similar to Human C9orf72 Expansion Carriers
(A) Fluorescence in situ hybridization (FISH) of sense and antisense RNA foci in F08-CTR (red box) and F112 C9-BAC mice. CER-GL, cerebellar granular layer;
CER-PC, cerebellar purkinje cells; hippo-DG, hippocampus dentate gyrus; FC, frontal cortex; PMC, primary motor cortex; SC-MN, spinal cord motor neuron.
Scale bar = 10 mm.
(B) Quantification of sense and antisense foci in nontransgenic (NTg), F08-CTR, and F112 C9-BACexp transgenic mice across brain regions. Lower graph shows
the percent of cells with foci across different brain regions at 3, 6, and 8 months of age.
(C) Immunostaining of poly(GP) in 20-month-old NTg or F112 C9-BACexp mice showing inclusions in brain regions including cortex, hippocampus dentate gyrus
(Hippo-DG), and cerebellar granular layer.
(D) Soluble poly(GP) is present in the cortex of 6-month-old C9-BACexp transgenic mice (F112 and F113), but not in NTg mice, nor F08-CTR mice, as assessed
using a poly(GP) immunoassay (n = 2 for F112, F113, NTG, and F08-CTR).
(E) Insoluble poly(GP) levels are lower than soluble poly(GP) levels (C) in the cortex of C9-BACexp transgenic mice, as determined by immunoassay of the
insoluble fraction (n = 2 for F112, F113, NTG, and F08-CTR).
(legend continued on next page)
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RESULTS
Generation of C9orf72 BAC Transgenic Mice
Wegenerated aBAC library from skin fibroblasts of aC9-ALSpa-
tient that had800 repeats bySouthern blot (Sareen et al., 2013).
BAC clone 239 was 174 kb and contained the complete
C9orf72 gene with the expansion (Figure 1A). Southern blot
confirmed that the GGGGCC expansion was present in the
BAC, but also highly unstable in bacteria (Figure S1A). To
generate control mice with a normal (2–30) repeat length, we
injected a subclone derived from BAC 239 that had stably con-
tracted to 15 repeats in bacteria, generating line F08-CTR (Fig-
ure S1A, Figure 1B). To generatemicewith expansions in the dis-
ease range (C9-BACexp), we injected a subclone that had a
major repeat size of 800 (Figure S1A). The resulting founders
showedavariety ofC9orf72 repeat sizes in thegenomeonSouth-
ern blot, ranging from 100 to 1,000 (Figure 1B). The banding
pattern remained stable between littermates (Figure S1B), and
lineF112showed little changeacross four generations, indicating
that the multiple repeat sizes represented BACs that were in-
serted into the genome as a single transgene array (Figure S1C).
No major shifts in repeat sizes were seen across tissues or brain
regions in individual mice, indicating that the repeats showed
relatively little somatic instability (Figure S1C). Quantitative RT-
PCR and western blot confirmed that the human C9orf72 tran-
script and protein were expressed (Figures 1C and 1D), and
C9orf72 protein levels were modestly increased (2-fold). For
further analysis we chose two C9-BACexp lines (F112 and
F113) as they showeda rangeof expansion sizes all in thedisease
range (100–1,000) and a similar level of transcript and protein
expression to the F08-CTR line. The C9orf72 hexanucleotide
repeat expansion occurs between two alternatively used up-
stream exons (1a and 1b) and is only transcribed in exon 1a-con-
taining isoforms.We therefore performed 50 rapid amplification of
cDNAends (50RACE) on spinal cord tissue and confirmed that the
human BAC expressed predominantly 1a (repeat-containing)
transcripts, similar to iPSC-derived motor neurons from the pa-
tient from which BAC 239 was derived (Figure 1E). Given that
repeat expansions can induce methylation and silencing of
C9orf72 transcription in humans, we performed a methylation-
sensitive restriction enzyme-qPCR toexamine transgenemethyl-
ation levels (Figure 1F) and observed that methylation was very
low in C9-BAC transgenic mouse lines. Of note, in the lines with
multiple insertions, the degree of expression from each of the
different transgenes cannot be ascertained.
C9-BACexp TransgenicMice Develop RNA Foci andDPR
Proteins Similar to Human C9orf72 Expansion Carriers
To examine the core pathologic features seen in C9orf72 expan-
sion patients, we surveyed brain regions in C9-BACexp trans-
genic mice for sense and antisense RNA foci. We observed
that C9-BACexp lines F112 and F113 showed both sense and(F) Immunoassay of poly(GP) levels in different brain regions. Cerebellum showe
(G) Comparison of poly(GP) levels in the cortex from C9-BAC mouse lines and C
levels to those detected in two different human C9orf72+ FTD frontal cortex sam
All data are shown as mean ± SEM. See also Figure S2.antisense RNA foci throughout the nervous system (Figure 2A).
By contrast, RNA foci were not observed in the F08-CTR line car-
rying 15 repeats (Figure 2A). In most brain regions, 40%–80%
of cells exhibited sense and antisense foci starting at 3months of
age, and they did not change in distribution or frequency over
time (Figure 2B).
Immunostaining showed that poly(GP) inclusions were rare in
brains of young mice (6 months), but were more frequent in the
brains of older mice (20 months), suggesting they accumulate
with age (Figure 2C). To quantitatively assess DPR production,
we utilized an immunoassay to detect poly(GP), a DPR protein
produced from both sense and antisense strands of the repeat
and abundantly expressed in C9-FTD brains. We found that
C9-BACexp mice showed abundant poly(GP) DPR proteins in
both the soluble and insoluble fractions fromas early as 6months
of age, which were not detected in nontransgenic mice or in
the F08-CTR line (Figures 2D and 2E). Poly(GP) DPR proteins
were most abundant in cerebellar tissue and least abundant in
spinal cord tissue, mirroring the distribution of DPR pathology
observed in C9orf72 expansion carriers (Davidson et al., 2014)
(Figure 2F). When run in parallel in the same immunoassay,
cortical tissue from C9-BACexp mice and C9-FTLD patients
showed quantitatively similar levels of soluble poly(GP) DPR
proteins (Figure 2G). These data indicate that C9-BACexp
mice develop sense and antisense RNA foci and widespread
DPR production in a distribution similar to that seen in human
C9orf72 expansion carriers.
Mice Carrying C9orf72 Hexanucleotide Expansions Do
Not Show Evidence of Neurodegeneration or Functional
Deficits in the Nervous System
Given the widespread RNA foci and DPR protein levels observed
in C9-BACexp mice, we examined line F112 for functional de-
fects in the nervous system. No abnormalities were seen in
body weight, grip strength, rotarod, or open field testing analysis
at either young (3 months) or advanced ages (18 months)
(Figures 3A–3D). Given that rodent models of FTLD can display
selective abnormalities in sociability and social novelty, we per-
formed the three-chamber test (Roberson, 2012) but found no
difference between nontransgenic and F112 C9-BAC mice (Fig-
ure 3E). Finally we performed the Y-maze test to assess memory
and novelty-seeking behavior, but again we observed no differ-
ence between C9-BACexp and nontransgenic control mice
(Figure 3F).
To interrogate the mice for evidence of ‘‘subclinical’’ levels of
frontal cortex or motor system damage, we examined them his-
tologically. No difference in neuromuscular junction innervation
or femoral axon counts were observed in C9-BACexp mice
compared to controls (Figures 3G–3I). Additionally, we per-
formed immunohistochemistry on the brains and spinal cords
of C9-BACexp mice, but found no evidence of protein aggrega-
tion (p62, TDP-43, ubiquitin), gliosis, inflammation, or synapse ord the highest levels, while levels were lowest in the spinal cord (n = 3).
9orf72-positive FTLD cases. Lines F112 and F113 produce poly(GP) at similar
ples (FTD #1 and FTD #2).
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Figure 3. C9-BAC Transgenic Mice Do Not Show Evidence of Neurodegeneration or Functional Deficits in the Nervous System
(A and B) Body weight (A) and grip strength (B) normalized to body weight at 18 months of age. For this and all behavioral studies below, male mice (NTg, n = 8;
F112, n = 10) were used unless otherwise indicated.
(C) Rotarod testing of cohorts of nontransgenic (NTg) and C9-BACexp mice (F112). No differences in sensorimotor coordination, or motor learning across trials,
were observed in either young (3 months; NTg, n = 8; F112, n = 8) or aged (18 months; NTg, n = 8; F112, n = 10) animals.
(D) Open field test at 18 months comparing total activity (left) and time spent in the center (right) for NTg mice and C9-BACexp (F112) mice.
(legend continued on next page)
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neuron loss (GFAP, IBA1, synaptophysin, and NeuN stain)
(Figure S2).
C9-BACexp Mice Have Evidence of Nucleolar Stress
without Downstream Sequelae
We first investigated colocalization of sense and antisense RNA
foci with the RNA binding proteins Pur a, hnRNPA3, hnRNPA2/
B1, and hnRNP-H, which were previously reported to bind to
GGGGCC-repeat-containing RNA foci in culture models and in
patient tissues (Lee et al., 2013; Xu et al., 2013). Surprisingly,
none of these RNA binding proteins showed sequestration, or
even consistent colocalization with sense or antisense RNA
foci in C9-BACexp transgenic mice (Figure S3). In addition to
altering RNA binding protein function, the C9orf72 expansion
was shown to disrupt nucleolar integrity by either binding the
G-quadraduplex structure of aborted transcripts to nucleolin
(Haeusler et al., 2014) or from arginine-containing dipeptide
repeat proteins that localize to the nucleolus and disrupt its func-
tion (Kwon et al., 2014; Wen et al., 2014). Interestingly, we
observed that C9-BACexp mouse neurons showed dispersion
of nucleolin from the nucleolus, similar to what has been
observed in cultured cells and nervous tissue from C9orf72
expansion patients (Figures 4A and 4B). While the partial misloc-
alization of nucleolin supports some degree of nucleolar stress,
we did not observe any downstream sequelae such as altered
RAN GTPase splicing or ribosomal RNA biogenesis (Figure S3).
To probe further for alterations in gene expression, we analyzed
transcriptomes by RNA-seq of spinal cord and cortex from 6-
month-old C9-BAC mice (F08-CTR, F112 C9-BACexp and non-
transgenic mice), an age at which RNA foci and DPR levels are
highly elevated. Gene set enrichment analysis (GSEA) identified
immunomodulatory and extracellular matrix pathways as sig-
nificantly enriched (FDR < 0.05) among genes downregulated
in the cortex of C9-BACexp compared to nontransgenic mice
(Figure S4). These pathways were not enriched among genes
downregulated in cortex from the F08-CTR line compared to
nontransgenic mice, indicating a specific effect in the C9-BA-
Cexpmice carrying the hexanucleotide expansion. Furthermore,
in comparing altered pathways with those observed in recently
published datasets using human C9orf72 patient cortex- or
iPSC-derived neurons (Donnelly et al., 2013), we found that
the dendritic cell pathway regulating TH1 and TH2 cell develop-
ment was downregulated in both the C9-BACexp mice and hu-
man iPSC-derived neurons compared to controls (Figure S4).
Together, these data suggest that the RNA foci, DPR proteins,
and nucleolar stress present in C9-BACexp mice alter RNA
expression in specific pathways promoting cellular dysfunction
that are shared with the human iPSC-derived neurons, but are
not sufficient to drive neurodegeneration.(E) Three-chamber test for sociability and social novelty at 16 months. F112 mice
neutral zone, no different from NTg mice.
(F) Y-maze assessment of memory and novelty seeking at 18 months was not d
(G) Neuromuscular junction staining (bungarotoxin, red; synaptophysin/neurofilam
20 months showed no differences in occupancy, fragmentation, or area (n = 6).
(H) Femoral motor and sensory nerve plastic sections from NTg, F08-CTR, and C
(I) Axon counts of femoral motor and sensory nerves (n = 6) in C9-BAC (F112) an
All data are shown as mean ± SEM. See also Figure S2.Suppression of RNA Foci and DPR Proteins with
Antisense Oligonucleotides in Primary Cortical Cultures
from C9-BACexp Mice
Finally, to examine phenotypes in C9-BACexp mice at the
cellular level, we generated primary cortical cultures from C9-
BACexp mice and compared them to nontransgenic controls.
FISH revealed RNA foci in 73% (SD ± 9%) of cultured neurons
and astrocytes from C9-BACexp mice (Figure 4C), which is
higher than the 20%–35% reported in human iPSC-derived neu-
rons from C9orf72 patients (Donnelly et al., 2013; Sareen et al.,
2013). No difference in the frequency of calcium transients (Fig-
ures 4D and 4E) or sensitivity to glutamate toxicity (Figures 4F
and 4G) was observed in cortical neurons cultured from C9-BA-
Cexp neurons. However, antisense oligonucleotides (ASOs) tar-
geting exon 2 of humanC9orf72were able to markedly suppress
both RNA foci and poly(GP) DPR proteins in primary cortical cul-
tures (Figures 4H–4J). These data indicate that cortical cells from
C9-BACexp mice recapitulate key features of C9orf72 expan-
sion pathology in vitro and demonstrate their utility for investi-
gating therapeutic approaches aimed at diminishing RNA foci
and DPR pathology produced at physiologic levels in mice.
DISCUSSION
Here we report that C9-BACexp mice exhibited the cardinal
pathologic features seen in patients, including sense and anti-
sense RNA foci and soluble DPR proteins at levels similar to
those seen in brains of FTLD patients. Despite this fact, C9-BA-
Cexp mice did not develop measurable neurodegeneration dur-
ing their lifespan. Notably, an independently generated C9orf72
BAC transgenic mouse reported by Peters, Cabrera et al. in this
same issue of Neuron (Peters et al., 2015) also expresses histo-
pathological features of C9orf72 repeat expansion without neu-
rodegeneration. This is consistent with animal models of many
neurodegenerative diseases, which typically mimic only certain
aspects of the human pathophysiology and frequently lack overt
neurodegeneration (Rockenstein et al., 2007). Additionally, many
mouse models require high-level overexpression driven by a
transgenic promoter to produce pathology, which opens the
possibility of emergent toxicities that do not relate to the human
disease being modeled. While this manuscript was being pre-
pared, mice expressing high levels of a synthetic C9orf72 repeat
under control of the chicken b-actin promoter using adeno-asso-
ciated virus were reported that make RNA foci and RAN peptides
and develop neurodegeneration (Chew et al., 2015). Importantly,
C9-BACexp mice show similar amounts of sense and antisense
RNA foci and DPR peptides to human disease tissues, without
requiring high levels of overexpression obtained using an exog-
enous promoter. This suggests that additional factors will beprefered spending time with the stranger and the novel object more than in the
ifferent between C9-BACexp mice and NTg controls.
ent, green) of the tibialis anterior muscle in NTg and C9-BACexp (F112) mice at
9-BACexp (F112) mice.
d control mice (NTg, F08-CTR) at 20 months of age.
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Figure 4. C9-BACexp Mice Show Evidence of Nucleolar Stress and Decreased RNA Foci and DPR Proteins after Antisense Oligonucleotide
Treatment
(A) Immunofluorescence staining of nucleolin (red) costained with DAPI (blue) in nontransgenic (NTg) and C9-BACexp (F112) mice in the cerebellar purkinje cells
(CER-PC), frontal cortex (FC), and primary motor cortex (PMC). C9-BACexpmice showed partial displacement of nucleolin from the nucleolus (scale bar, 20 mm).
(B) Quantitation of nucleolin staining distribution revealed a shift in the ratio of the amount of staining in the nucleus versus the nucleolus (n = 4 animals; two-sided t
test, NTg versus F112; *p < 0.05; **p < 0.01).
(C) RNA FISH of sense foci in primary cortical cultures from neonatal NTg and F113 C9-BACexp mice. RNA foci were observed in 73% (±9%) of neurons and
astrocytes.
(legend continued on next page)
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needed to drive neurodegeneration from expression of the
C9orf72 repeat at normal physiologic levels in mice.
Studies have supported a variety of potential gain-of-function
toxicities resulting from the C9orf72 hexanucleotide expansion
expression. These include RNA toxicity from sequestration of
RNA-binding proteins by RNA foci (Donnelly et al., 2013; Lee
et al., 2013; Sareen et al., 2013), ER stress or Unc119 sequestra-
tion from poly(GA) DPR aggregates (May et al., 2014; Zhang
et al., 2014), and nucleolar stress from either G-quadraduplex-
containing RNA transcripts (Haeusler et al., 2014) or arginine
(PR/GR)-containing DPR proteins (Kwon et al., 2014; Mizielinska
et al., 2014; Tao et al., 2015; Wen et al., 2014). While sense and
antisense RNA foci were widespread throughout the nervous
system, C9-BACexp mice surprisingly did not show binding or
sequestration of RNA-binding proteins previously reported to
interact with foci. The variability in sequestered RNA-binding
proteins from the different published reports suggests that
none of the RNA-binding proteins reported thus far is likely a
pivotal player in C9orf72 pathogenesis. By contrast, we did
observe altered localization of nucleolin suggestive of mild
nucleolar stress, but despite this we did not observe any down-
stream sequelae such as altered ribosomal RNA biogenesis or
altered splicing events. This difference may be due to the severe
toxicity seen in the acute overexpression culture models or
because the reported sequelae of altered nucleolin localization
occur relatively late in the cascade of neurodegeneration caused
by the C9orf72 expansion.
It is notable thatmacroscopic p62-positive DPRprotein aggre-
gates were only observed in the brain tissues of agedmice, while
the poly(GP) immunoassay showed soluble DPR protein levels in
younger mice, suggesting that altered protein homeostasis with
age leads to accumulation of insoluble DPR aggregates. Regard-
less, there remains controversy as to whether the macroscopic
DPR aggregates play a key role in C9orf72 repeat pathogenesis,
since their distribution has little relationship to the clinical pheno-
type in ALS and FTLD patients, with the highest degree of pathol-
ogy typically in the cerebellum and relatively little in the spinal
cord (Davidson et al., 2014; Mann, 2015).
While the C9-BACexp mice focus on modeling gain-of-func-
tion manifestations in C9orf72 expansion carriers, partial loss
of C9orf72 function due to epigenetic silencing remains a poten-
tial contributor in disease pathogenesis. Decreased expression
of C9orf72 transcripts has been reported (DeJesus-Hernandez
et al., 2011; Gijselinck et al., 2012), as have epigenetic modifica-
tions of the repeat-containing allele that may be either detri-
mental or protective (Belzil et al., 2013; Russ et al., 2015; Xi
et al., 2013). The C9orf72 protein has been reported to regulate(D) Representative calcium recording from culture cortical neurons (NTg, top; F1
(E) Frequency of calcium transients observed quantitated using Fluo-4 live imag
(F) Glutamate toxicity assay in primary cortical neuron cultures showing Tuj1 staini
(G) The number of neurons (TuJ1 positive) were divided by total number of cells (DA
and NTg.
(H) RNA FISH of sense foci in primary cortical cultures treated with either control
C9orf72 transcript (C9 ASO).
(I) Quantification of RNA foci reduction after C9 ASO treatment (**p = 0.004, two
(J) Immunoassay showing reduction of poly(GP) DPR proteins in cortical cultures
(**p = 0.004, one-way ANOVA).
All data are shown as mean ± SEM. See also Figure S3.endosomal trafficking in cultured cells (Farg et al., 2014), and loss
of theC9orf72 ortholog in zebrafish orworms led tomotor deficits
(Ciura et al., 2013; Therrien et al., 2013). While the C9-BACexp
mice cannot resolve whether C9orf72 expansion pathogenesis
involves a component of loss of function, they do argue that
RNA foci andRANdipeptides alone arenot sufficient todrive neu-
rodegeneration. This is in keepingwith several observations from
human C9orf72 patient genetics and pathology. First, the
C9orf72 expansion is not completely penetrant, appearing in
both normal elderly individuals and up to 0.6% of normal control
populations of European or North American origin (Galimberti
et al., 2014; Harms et al., 2013). This supports the hypothesis
that additional environmental or genetic factors are required
for neurodegeneration to manifest as a consequence of the
C9orf72 expansion mutation. Second, accumulation of DPR pa-
thology clearly predates and does not correspond regionally to
neurodegeneration in humans, which instead correlates with
TDP-43 pathology (Baborie et al., 2015; Proudfoot et al., 2014).
Given that the C9-BACexp mice display these early features of
RNA foci and DPR proteins without neurodegeneration or TDP-
43 pathology, we propose that they are recapitulating the pre-
symptomatic phase of disease seen in humans, which requires
additional insults (genetic, environmental, and/or aging) to fully
manifest and lead to neurodegeneration. This makes them
extremely useful for studying early stages of disease pathogen-
esis and to identify additional stressors that promote neurode-
generation in C9orf72 expansion carriers. Finally, they will be an
invaluable tool for investigating therapeutic strategies that alter
RNA foci and DPR pathology, as we found that ASOs targeting
the human C9orf72 transcript were able to significantly diminish
the RNA foci burden and poly(GP) levels in cultured cortical cells.
EXPERIMENTAL PROCEDURES
All studies were conducted in accordance with the protocols described by
the National Institutes of Health’s Guide for the Care and Use of Animals
and approved by The Jackson Laboratory and Cedars-Sinai Institutional Ani-
mal Care and Use Committees. Studies using human tissues were conducted
under protocols approved by the Institutional Review Boards of Cedars-
Sinai and Mayo Clinic Jacksonville. Mice are available from The Jackson Lab-
oratory with the following catalog numbers: 23099, C57BL/6J-Tg(C9orf72_3)
112Lutzy/J; 23100, C57BL/6J-Tg(C9orf72_3)113Lutzy/J; 23088, C57BL/6J-
Tg(C9orf72_2)8Lutzy/J.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.neuron.2015.10.027.12, bottom).
ing (n = 27, NTg; n = 68, F112).
ng after 24 hr of glutamate treatment at the indicated dose (scale bar = 400 mm).
PI, not shown) and then normalized to the controls (no treatment) for both F113
antisense oligonucleotides (Scr ASO) or an ASO targeting exon 2 of the human
-sided t test).
from C9-BACexp (F112 line) mice treated with C9 ASO compared to Scr ASO
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